NCT03793361 2026-03-18
EREMISS
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
90 trialsNCT01900743 2026-03-13
REGO-SARC
Centre Oscar Lambret
Phase 2 Completed
NCT02386397 2026-03-12
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT06071052 2026-03-05
DREAM
First Affiliated Hospital, Sun Yat-Sen University
Phase 2 Completed
NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT03712943 2026-02-09
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04362839 2026-01-28
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03994601 2026-01-20
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06095375 2026-01-09
REGOMA-2
Istituto Oncologico Veneto IRCCS
Phase 1 Completed
NCT03042689 2026-01-08
Study of Regorafenib in Patients With Advanced Myeloid Malignancies
Massachusetts General Hospital
Phase 1 Completed
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04660812 2025-10-20
ARC-9
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT05064059 2025-09-17
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02098538 2025-09-10
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04874207 2025-08-08
RePERSO
Rennes University Hospital
Phase 4 Completed
NCT02368886 2025-06-18
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT04051606 2025-06-05
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT04704154 2025-04-18
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
Phase 2 Completed
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT03627728 2025-03-13
a-MANTRA
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT03406871 2025-01-24
REGONIVO
National Cancer Center Hospital East
Phase 1 Completed
NCT04534218 2024-12-20
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT03564938 2024-12-03
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
Bayer
Phase 4 Completed
NCT02175095 2024-10-04
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Asan Medical Center
Phase NA Completed
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT03890731 2024-04-02
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Phase 2 Completed
NCT02316340 2024-01-05
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02195011 2023-12-05
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02795156 2023-12-05
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02024607 2023-11-15
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03215264 2023-11-09
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02048371 2023-11-07
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT02584465 2023-09-06
REGOVAR
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT03520842 2023-08-01
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Stanford University
Phase 2 Completed
NCT04126733 2023-07-18
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Bayer
Phase 2 Completed
NCT02638766 2023-03-27
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT04310709 2022-12-06
RENOBATE
Asan Medical Center
Phase 2 Completed
NCT02307500 2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2 Completed
NCT02926222 2022-09-09
REGOMA
Istituto Oncologico Veneto IRCCS
Phase 2 Completed
NCT02736305 2022-06-13
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
National Cancer Centre, Singapore
Phase 2 Completed
NCT04200404 2022-05-06
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Completed
NCT02080260 2022-04-21
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
Wake Forest University Health Sciences
Phase 2 Completed
NCT03475251 2022-02-18
A Study of CS1003 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT02115542 2021-10-12
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02164240 2021-06-14
SURE
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02095054 2021-04-01
Regorafenib and Cetuximab in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03305913 2021-03-26
REMETY
AIO-Studien-gGmbH
Phase 1 Completed
NCT00664326 2021-01-29
A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
Bayer
Phase 2 Completed